|
Leveraging BCMA-Directed Therapies for Improved Patient Outcomes in Relapsed/Refractory Multiple Myeloma
STATEMENT OF NEED
Multiple myeloma is a disease that remains incurable for most patients, many of whom become refractory to the majority of available treatments (Kumar et al, 2022). It is estimated that 35,730 new cases of multiple myeloma are diagnosed in the United States annually, and 12,590 people die of the disease (Siegel et al, 2023). Agents targeting B-cell maturation antigen (BCMA), including antibody-drug conjugates (ADCs), chimeric antigen receptor (CAR) T-cell therapies, and bis... |
|
|
Expert Guidance on Current Standards and New Directions in Newly Diagnosed Multiple Myeloma
STATEMENT OF NEED
An estimated 35,730 new cases of multiple myeloma are diagnosed in the United States annually, and 12,590 people die of the disease (Siegel et al, 2023). Characterized by clonal proliferation of malignant plasma cells in the bone marrow, multiple myeloma is associated with anemia, renal insufficiency, bone destruction, and hypercalcemia, all of which significantly impact patients’ quality of life. The development of novel therapies and combinations in recent years, inclu... |
|
|
Exploring New Treatment Advances for Acid Sphingomyelinase Deficiency in Adults
STATEMENT OF NEED
Acid sphingomyelinase deficiency (ASMD) is a rare, hereditary lysosomal storage disease with multisystemic manifestations, including splenomegaly, hepatomegaly, interstitial lung disease, dyslipidemia, bone marrow and lymph node involvement, and sometimes neurological and peripheral nerve involvement. While the most severe form of ASMD, infantile neurovisceral ASMD, results in death in early childhood, chronic forms of ASMD have more prolonged survival but are associated w... |
|
|
Real-World Perspectives in Managing CLL Treatment
Management options for chronic lymphocytic leukemia (CLL) have expanded in recent years. The emergence of new immunotherapeutic and targeted agents for both the first-line and relapsed/refractory settings"though of course beneficial for CLL patients"represents a challenge to clinicians, who must navigate the indicated uses, mechanisms of action, and toxicity profiles of these new agents. In determining optimal treatment plans, clinicians are also confronted with significant advances ... |
|
|
Graft vs Host Disease: Novel Management Strategies for a Chronic Condition
Target Audience
The intended audience for this activity is transplant specialists, oncologists, hematologists, and other healthcare professionals involved in the treatment of patients with GVHD.
Program Overview
This enduring activity takes learners on a compelling journey in managing chronic graft-versus-host disease (cGVHD) by explaining the evidence-based diagnostic criteria for cGVHD for prompt diagnosis; discussing the clinical safety and efficacy data of recently approved and invest... |
|
|
Clinical Updates in Chronic Graft-versus-Host Disease and Applications for Academic and Community Practice
Target Audience
The target audience for this activity are hematologists, oncologists, immunologists, and bone-marrow transplant specialists.
Program Overview
Chronic graft-versus-host disease (cGvHD) is a common, multi-symptom complication of allogeneic transplantation that severely affects patient well-being. While the medical systems and resources differ between academic and community healthcare settings, clinicians practicing in both environments would benefit from education about rece... |
|
|
Hitting The Bullseye in NSCLC
Lung cancer is the second most common cancer in both men and women and is the leading cause of cancer-related deaths. The majority of lung cancer cases are categorized as NSCLC, which has a low overall 5-year survival rate, especially when it is diagnosed at advanced, unresectable stages. Recent advances in the treatment landscape have yielded promising improvements in progression-free survival and overall survival; however, outcomes are dependent on numerous factors, including the evaluation ... |
|
|
Applying Evolving Targeted Therapy in Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is a biologically heterogeneous hematologic malignant neoplasm with a 5-year survival rate of 30%. Hematologist, Brian Jonas, MD, PhD, UC Davis Comprehensive Cancer, discusses standard induction, consolidation, and maintenance therapy, as well as factors to consider in individualizing intensive therapy in fit and unfit patients. Dr. Jonas presents safety and efficacy data for approved and emerging therapies that target BCL-2, FLT-3 ITD/TDK, CD33, CD47, IDH1/2, E-se... |
|
|
Answering The Call in Nonadvanced Systemic Mastocytosis
Target Audience
The design of this activity addresses the needs of clinical immunologists/allergists, dermatologists, gastroenterologists, hematologists, and other specialist clinicians who diagnose or manage nonadvanced systemic mastocytosis (SM).
Program Overview
Nonadvanced SM is a challenging disorder to diagnose and manage due to the heterogeneity of symptoms, anaphylactic triggers, and complicated therapeutic paradigm. In this unique and engaging Call-a-Colleague program, a panel of... |
|
|
Individualized Strategies for Relapsed/Refractory Multiple Myeloma: Navigating Complexity with BCMA-Targeted and Novel Bispecific Antibodies
The expanding armamentarium of therapies for R/R MM shifts therapy selection from an algorithmic approach to an individualized strategy that requires consideration of the nature of relapse, prior therapies, treatment-related toxicities, as well as patient comorbidities and preferences. With the introduction of novel bispecific antibodies, specialists must learn how to optimally sequence these therapies and manage adverse events. To help clinicians navigate this complexity, individualized educa... |
|
|
Addressing Key Questions About BCMA-Targeted Therapy for Relapsed/Refractory Multiple Myeloma
ACTIVITY DESCRIPTION
Though treatment advances have improved outcomes for most patients, MM remains an incurable disease characterized by continuous relapse. However, the treatment landscape for relapsed/refractory MM (RRMM) has expanded in recent years, and patients who relapse and/or become refractory to initial therapies are benefiting from the increasing availability of a diverse range of novel agents, including B-cell maturation antigen (BCMA)"targeted immunotherapies. These agents ... |
|
|
Advances in™ Beta-Thalassemia: The Evolving Therapeutic Landscape
Target Audience
This educational activity is directed toward hematologists and hematologist-oncologists, as well as pediatricians, nurses, nurse practitioners, physician assistants, and other clinicians involved in the management of patients with beta-thalassemia.
Program Overview
This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of β-thalassemia, with a forward-looking perspective on how new and novel agents might imp... |
|